BioSpace News Archive

Increase in trends of outsourcing services owing to benefits offered by outsourced compliance providers over in-house compliance functions, and increase in adverse drug reactions and drug toxicity, boost growth of the market.

NeuroOne Medical Technologies Corporation announces today that it has executed an agreement with RBC Medical Innovations to develop and manufacture a proprietary radiofrequency (RF) generator for use with NeuroOne’s combination recording and ablation electrode that is being designed to both record brain activity and ablate brain tissue using the same electrode.

Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe.

BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a 40,000 ft2 commercial oral solid dose manufacturing facility located at 72 Fairbanks, Irvine, CA, USA.

The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the New York City Department of Health and Mental Hygiene (NYC Health Department) a thirty-month grant to support long-acting injectable antiretroviral therapy access, uptake, and adherence among people with HIV enrolled in the Ryan White HIV/AIDS Program (hereafter “Ryan White”).

Genscript Biotech (HKEX: 1548.HK) (GenScript), a global leading biotech company, today announced its audited financial results for the year ended June 30, 2021.

Monoclonal antibody treatment is intended for people who are at a high risk of serious illness.

SI-BONE, Inc.today announced that it will be participating in the following upcoming investor conferences: 19 th Annual Morgan Stanley Global Healthcare Conference Fireside Chat on Tuesday, September 14, 2021, 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present a company overview at the Ophthalmology Futures European 2021 Virtual Retina Forum on September 8, 2021

Medline ReNewal today announced the launch of a continuing education (CE) course series to help cardiac electrophysiology (EP) clinicians learn more about the fundamentals of cardiac EP lab procedures.